Bluejay Diagnostics raises $4.5M in private placement of stock and warrants

Bluejay Diagnostics, Inc.

Gross proceeds of $4.5M; net proceeds ~$4.0M after 8% placement agent fee and expenses.
Issued 2.25M shares/pre-funded warrants at $2.00/unit plus Series F warrants for 4.5M shares at $1.75.
Net proceeds to fund FDA approval efforts, clinical studies, R&D, and working capital.
Rodman & Renshaw acted as exclusive placement agent; warrants include 4.99%/9.99% beneficial ownership caps.
Company agreed to file resale registration statement by Oct 24, 2025, and has 90-day issuance lock-up post-effectiveness.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Bluejay Diagnostics, Inc. issued 175,000 shares of common stock to institutional, accredited investors for $2.00 per share.

Security: common stock
Shares: 175,000 shares
Purchaser: institutional, accredited investors
Consideration: $2.00 per share

Exact text from the filing

and (ii) Series F warrants (“Series F Warrants”) to purchase up to 4,500,000 shares of common stock. The combined price of securities sold in the private placement was $2.00 per share of common stock (or pre-funded warrant in lieu thereof, in which case such price was reduced by $0.0001) and accompanying Series F Warrants to acquire two shares of

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Bluejay Diagnostics, Inc. issued Placement Agent Warrants to purchase up to an aggregate of 180,000 shares of common stock of warrant to Rodman and Renshaw LLC (placement agent) for 125% of the combined price per share.

Security: warrant
Shares: Placement Agent Warrants to purchase up to an aggregate of 180,000 shares of common stock
Purchaser: Rodman and Renshaw LLC (placement agent)
Consideration: 125% of the combined price per share

Exact text from the filing

the “common warrants”) to purchase up to an aggregate of 180,000 shares of common stock on the same terms as the Series F Warrants, except that the exercise price per share is 125% of the combined price per share and Series F Warrants sold in the offering. Pursuant to the terms of the registration rights agreement, the Company has agreed to register for

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Bluejay Diagnostics, Inc. issued Series F Warrants to purchase up to 4,500,000 shares of common stock of warrant to institutional, accredited investors for $2.00 per share.

Security: warrant
Shares: Series F Warrants to purchase up to 4,500,000 shares of common stock
Purchaser: institutional, accredited investors
Consideration: $2.00 per share

Exact text from the filing

and (ii) Series F warrants (“Series F Warrants”) to purchase up to 4,500,000 shares of common stock. The combined price of securities sold in the private placement was $2.00 per share of common stock (or pre-funded warrant in lieu thereof, in which case such price was reduced by $0.0001) and accompanying Series F Warrants to acquire two shares of

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Bluejay Diagnostics, Inc. issued Pre-Funded Warrants to purchase up to 2,075,000 shares of common stock of warrant to institutional, accredited investors for $2.00 per share.

Security: warrant
Shares: Pre-Funded Warrants to purchase up to 2,075,000 shares of common stock
Purchaser: institutional, accredited investors
Consideration: $2.00 per share

Exact text from the filing

and (ii) Series F warrants (“Series F Warrants”) to purchase up to 4,500,000 shares of common stock. The combined price of securities sold in the private placement was $2.00 per share of common stock (or pre-funded warrant in lieu thereof, in which case such price was reduced by $0.0001) and accompanying Series F Warrants to acquire two shares of

View on SEC.gov

25 equity issuances filed in the last 30 days. Browse all equity issuances →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-098281

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.